FDA’s Review Process Shows Preferential Treatment of NMEs for Unmet Medical Needs
This week FDA posted a review of its drug approval process based on the principle of benefit-risk-assessment that shows it gives special consideration to new molecular entities (NMEs) intended for diseases with few or no treatment options with regards to market approval decisions. Over the last decade, FDA emphasized the value of putting the safety … Read more
